Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.81 |
| ▸ | RAB9A | P51151 | 4/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.71 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.70 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.64 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.64 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29768474 | 0.90 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2KCNK3KCNK9 | |
| SCHEMBL28579555 | 0.90 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2KCNK3KCNK9 | |
| SCHEMBL3794687 | 0.89 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2KCNK3KCNK9 | |
| SCHEMBL30462972 | 0.88 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2KCNK3KCNK9 | |
| SCHEMBL13972812 | 0.88 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2KCNK3KCNK9 | |
| SCHEMBL4250050 | 0.88 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2KCNK3KCNK9 | |
| Iodide SCHEMBL30758613 | 0.88 | NPC1 (0.97) | NPC1RAB9ASMN1; SMN2KCNK3KCNK9 | |
| SCHEMBL3675463 | 0.87 | KCNK3 (0.84) | NPC1RAB9ASMN1; SMN2KCNK3KCNK9 | |
| SCHEMBL15045216 | 0.87 | NPC1 (0.82) | NPC1RAB9ASMN1; SMN2KCNK3KCNK9 | |
| SCHEMBL4698582 | 0.86 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| EP-0773249-B1 | Polyphenylene co-polymers | MISSISSIPPI POLYMER TECHNOLOGI (US) | 2002-10-02 | — | — | EP | disclosed |
| US-5886130-A | THE CO-POLYMERS ARE USEFUL AS MOLDING RESINS, AND COMPOSITE MATRIX RESINS, AND WHERE AR IS HETEROARYLENE AS ION EXCHANGE RESINS. | MAXDEM INCORPORATED (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0773249-A1 | Polyphenylene co-polymers | MAXDEM INCORPORATED (US) | 1997-05-14 | — | — | EP | disclosed |
| US-4499167-A | Photoconductive compositions comprising an organic photoconductor and an amide compound and electro-photographic light-sensitive materials using the compositions | FUJI PHOTO FILM CO., LTD. (JP) | 1985-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | NPC1 869/4885RAB9A 733/4885SMN1; SMN2 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.